Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.20.4
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Condensed Consolidated Statements of Operations and Comprehensive Loss        
Revenues $ 705 $ 314 $ 1,115 $ 422
Operating expenses:        
Research and development (related party of $0, $0, $0 and $97) 2,444 888 4,206 1,865
General and administrative (related party of $510, $304, $903 and $572) 5,806 2,581 11,378 5,567
Total operating expenses 8,250 3,469 15,584 7,432
Operating loss (7,545) (3,155) (14,469) (7,010)
Other income (expense):        
Interest expense (related party of $612, $615, $1,226 and $1,235) (615) (615) (1,229) (1,235)
Interest income 27 4 31 8
Royalty income 2 2 2 9
Total other income (expense) (586) (609) (1,196) (1,218)
Consolidated net loss (8,131) (3,764) (15,665) (8,228)
Net loss attributable to noncontrolling interest 2 2 3 3
Net loss attributable to iBio, Inc. (8,129) (3,762) (15,662) (8,225)
Preferred stock dividends - iBio CMO Tracking Stock (65) (65) (131) (131)
Deemed dividends - down round of Series A Preferred and Series B Preferred   (21,560) 0 (21,560)
Net loss available to iBio, Inc. stockholders (8,194) (25,387) (15,793) (29,916)
Comprehensive loss:        
Consolidated net loss (8,131) (3,764) (15,665) (8,228)
Other comprehensive loss - unrealized loss on securities (13)   (20) 0
Other comprehensive loss - foreign currency translation adjustments   1 0 (1)
Comprehensive loss $ (8,144) $ (3,764) $ (15,685) $ (8,229)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.04) $ (0.69) $ (0.09) $ (1.02)
Weighted-average common shares outstanding - basic and diluted 188,087 36,917 175,264 29,420